Cell Metabolism:重大进展!迟洪波团队揭示代谢调控 Treg 细胞机制,或为自身免疫病治疗提供新靶点

2020-11-24 丁香学术 iNature

效应调节性 T(eTreg)细胞对于免疫耐受至关重要,了解 eTreg 细胞分化和维持的调控机制对于自身免疫性疾病、癌症和传染病均具有重要意义。

效应调节性 T(eTreg)细胞对于免疫耐受至关重要,了解 eTreg 细胞分化和维持的调控机制对于自身免疫性疾病、癌症和传染病均具有重要意义。然而,到目前为止尚不清楚代谢途径如何调节 eTreg 细胞分化和维持。

美国圣犹达儿童研究医院迟洪波教授团队在 Cell Metabolism 上在线发表了题为 Protein Prenylation Drives Discrete Signaling Programs for the Differentiation and Maintenance of Effector Treg Cells 的研究成果。

该研究揭示了代谢依赖的翻译后异戊烯化修饰在 eTreg 细胞介导的免疫抑制中的至关重要的作用。

研究内容

调节性 T(Treg)细胞对于建立自身免疫耐受至关重要,这一作用依赖于在稳态和炎症过程中央 Treg(cTreg)细胞向效应 Treg(eTreg)细胞的转化。与 cTreg 细胞相比,eTreg 细胞显示出卓越的抑制活性,并增强了对非淋巴组织的耐受性。

代谢指导 Treg 细胞的功能,但是支持 eTreg 细胞的具体代谢程序尚不清楚。

作者发现,与静息 Treg 细胞相比,活化的 Treg 细胞中参与介导胆固醇生物合成和类异戊二烯依赖性翻译后脂质修饰的多个基因的表达上调。TCR 激活诱导了甲羟戊酸途径和类异戊二烯依赖性蛋白异戊二烯化的基因表达变化。

图片来源:Cell Metabolism

由于类异戊二烯介导蛋白质异戊二烯化,作者接下来测试了类异戊二烯是否通过翻译后脂质修饰建立了 Treg 细胞功能。在条件性敲除小鼠 Treg 细胞中的 Fntb 或 Pggt1b 基因后,这些小鼠表现出身材矮小,全身性炎症和快速死亡的特征,表明 Treg 细胞中的 Fntb 和 Pggt1b 有着控制免疫稳态的作用。

图片来源:Cell Metabolism

进一步地研究发现,Fntb 和 Pggt1b 对于 eTreg 细胞的积累至关重要,但这两个基因分别调控着 eTreg 细胞稳态的不同方面。Fntb 对于 cTreg 细胞激活和分化为 eTreg 细胞是必不可少的,但可能有助于 eTreg 细胞的维持,而 Pggt1b 在 cTreg 细胞激活过程中促进 eTreg 细胞分化。

为了探索 Fntb 依赖的 eTreg 细胞维持的机制,作者通过 GSEA 分析发现,在抑制了 Fntb 后 mTORC1 的激活显着降低。进一步的实验确认 Fntb 而不是 Pggt1b,对于 TCR 刺激的 cTreg 细胞中的 mTORC1 激活至关重要。

图片来源:Cell Metabolism

GGTI(抑制 Pggt1b)处理可抑制 cTreg 细胞的 TCR 激活后 CD5 和 Nur77-GFP 的上调,表明 Pggt1b 调谐 TCR 信号。此外,为了接收 TCR 信号,Treg 细胞与 T 细胞区域中的抗原呈递树突状细胞(DC)相互作用。Pggt1b 缺陷型 Treg 细胞对 DC 的粘附力降低,在 eTreg 细胞中观察到更明显的缺陷,表明 Pggt1b 对于促进 Treg 细胞对 DC 的粘附至关重要。

图片来源:Cell Metabolism

为了确定 Pggt1b 的可能分子靶标,作者使用了独创性的途径分析,该途径预测了 Pggt1b 缺陷型 Treg 细胞(包括 Rac 信号传导)中的几种经典途径均被下调。进一步的实验表明 Rac 信号有助于 Pggt1b 下游的 TCR 依赖性激活和 eTreg 细胞分化。

图片来源:Cell Metabolism

研究总结

图片来源:Cell Metabolism

在本研究中,作者发现了在 eTreg 细胞分化和维持过程中免疫受体和代谢依赖性翻译后脂质修饰之间的双向代谢信号传导机制。

具体而言,源自甲羟戊酸代谢途径的类异戊二烯建立活化的 Treg 的抑制活性,以及类异戊二烯依赖性蛋白的法尼基化和香叶酰化是免疫耐受所必需的,这些过程分别由 Fntb 和 Pggt1b 介导。

此外,作者还确定了 Fntb 对 mTORC1 活性和 ICOS 表达的特定促进作用,以维持 eTreg 细胞,而 Pggt1b 介导 TCR 激活和 Rac 信号传导 eTreg 细胞分化。

本研究确定了细胞代谢与 eTreg 细胞分化和维持所必需的蛋白质翻译后脂质修饰之间的关键联系。Fntb 和 Pggt1b 调节不同的信号通路和细胞功能的发现可能为选择性调节自身免疫性疾病、癌症和传染病中的 Treg 细胞活性提供了潜在的靶点。

「我们能够研究代谢调节如何控制 eTreg 细胞的分化和维持,」文章一作 Wei Su 说,「细胞内信号传导和新陈代谢之间的这种双向相互作用使 eTreg 细胞能够维持我们体内的自我耐受性。」

「这些途径作为一种抑制炎症反应的方式,而且是免疫系统之外的,一直受到人们的关注,我们的研究对信号与代谢之间的分子相互作用提出了新见解,有助于让 Treg 细胞中下游代谢功能更有效和更有针对性。」

原始出处:

Wei Su, Nicole M Chapman, Jun Wei, et al.Protein Prenylation Drives Discrete Signaling Programs for the Differentiation and Maintenance of Effector T reg Cells.Cell Metab. 2020 Nov 11;S1550-4131(20)30591-X. doi: 10.1016/j.cmet.2020.10.022.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1962373, encodeId=8fb919623e32e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 15 07:09:49 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896781, encodeId=1b511896e8155, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 20 20:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041785, encodeId=c0602041e851c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 29 07:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814549, encodeId=b7871814549a4, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Jun 22 10:09:49 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888245, encodeId=097f1888245e2, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Dec 27 20:09:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872071, encodeId=ecb518e207166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 13:09:49 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905539, encodeId=267690553996, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Dec 06 23:25:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288312, encodeId=38d412883124b, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291737, encodeId=d66c1291e372c, content=<a href='/topic/show?id=62f68635461' target=_blank style='color:#2F92EE;'>#自身免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86354, encryptionId=62f68635461, topicName=自身免疫病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477217, encodeId=751514e72175e, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
    2021-10-15 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1962373, encodeId=8fb919623e32e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 15 07:09:49 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896781, encodeId=1b511896e8155, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 20 20:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041785, encodeId=c0602041e851c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 29 07:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814549, encodeId=b7871814549a4, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Jun 22 10:09:49 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888245, encodeId=097f1888245e2, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Dec 27 20:09:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872071, encodeId=ecb518e207166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 13:09:49 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905539, encodeId=267690553996, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Dec 06 23:25:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288312, encodeId=38d412883124b, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291737, encodeId=d66c1291e372c, content=<a href='/topic/show?id=62f68635461' target=_blank style='color:#2F92EE;'>#自身免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86354, encryptionId=62f68635461, topicName=自身免疫病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477217, encodeId=751514e72175e, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
    2021-07-20 仁者大医
  3. [GetPortalCommentsPageByObjectIdResponse(id=1962373, encodeId=8fb919623e32e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 15 07:09:49 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896781, encodeId=1b511896e8155, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 20 20:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041785, encodeId=c0602041e851c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 29 07:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814549, encodeId=b7871814549a4, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Jun 22 10:09:49 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888245, encodeId=097f1888245e2, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Dec 27 20:09:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872071, encodeId=ecb518e207166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 13:09:49 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905539, encodeId=267690553996, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Dec 06 23:25:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288312, encodeId=38d412883124b, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291737, encodeId=d66c1291e372c, content=<a href='/topic/show?id=62f68635461' target=_blank style='color:#2F92EE;'>#自身免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86354, encryptionId=62f68635461, topicName=自身免疫病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477217, encodeId=751514e72175e, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1962373, encodeId=8fb919623e32e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 15 07:09:49 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896781, encodeId=1b511896e8155, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 20 20:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041785, encodeId=c0602041e851c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 29 07:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814549, encodeId=b7871814549a4, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Jun 22 10:09:49 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888245, encodeId=097f1888245e2, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Dec 27 20:09:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872071, encodeId=ecb518e207166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 13:09:49 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905539, encodeId=267690553996, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Dec 06 23:25:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288312, encodeId=38d412883124b, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291737, encodeId=d66c1291e372c, content=<a href='/topic/show?id=62f68635461' target=_blank style='color:#2F92EE;'>#自身免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86354, encryptionId=62f68635461, topicName=自身免疫病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477217, encodeId=751514e72175e, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1962373, encodeId=8fb919623e32e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 15 07:09:49 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896781, encodeId=1b511896e8155, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 20 20:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041785, encodeId=c0602041e851c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 29 07:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814549, encodeId=b7871814549a4, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Jun 22 10:09:49 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888245, encodeId=097f1888245e2, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Dec 27 20:09:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872071, encodeId=ecb518e207166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 13:09:49 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905539, encodeId=267690553996, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Dec 06 23:25:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288312, encodeId=38d412883124b, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291737, encodeId=d66c1291e372c, content=<a href='/topic/show?id=62f68635461' target=_blank style='color:#2F92EE;'>#自身免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86354, encryptionId=62f68635461, topicName=自身免疫病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477217, encodeId=751514e72175e, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
    2020-12-27 guojianrong
  6. [GetPortalCommentsPageByObjectIdResponse(id=1962373, encodeId=8fb919623e32e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 15 07:09:49 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896781, encodeId=1b511896e8155, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 20 20:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041785, encodeId=c0602041e851c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 29 07:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814549, encodeId=b7871814549a4, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Jun 22 10:09:49 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888245, encodeId=097f1888245e2, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Dec 27 20:09:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872071, encodeId=ecb518e207166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 13:09:49 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905539, encodeId=267690553996, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Dec 06 23:25:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288312, encodeId=38d412883124b, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291737, encodeId=d66c1291e372c, content=<a href='/topic/show?id=62f68635461' target=_blank style='color:#2F92EE;'>#自身免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86354, encryptionId=62f68635461, topicName=自身免疫病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477217, encodeId=751514e72175e, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1962373, encodeId=8fb919623e32e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 15 07:09:49 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896781, encodeId=1b511896e8155, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 20 20:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041785, encodeId=c0602041e851c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 29 07:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814549, encodeId=b7871814549a4, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Jun 22 10:09:49 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888245, encodeId=097f1888245e2, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Dec 27 20:09:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872071, encodeId=ecb518e207166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 13:09:49 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905539, encodeId=267690553996, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Dec 06 23:25:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288312, encodeId=38d412883124b, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291737, encodeId=d66c1291e372c, content=<a href='/topic/show?id=62f68635461' target=_blank style='color:#2F92EE;'>#自身免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86354, encryptionId=62f68635461, topicName=自身免疫病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477217, encodeId=751514e72175e, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
    2020-12-06 gqylhd

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1962373, encodeId=8fb919623e32e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 15 07:09:49 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896781, encodeId=1b511896e8155, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 20 20:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041785, encodeId=c0602041e851c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 29 07:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814549, encodeId=b7871814549a4, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Jun 22 10:09:49 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888245, encodeId=097f1888245e2, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Dec 27 20:09:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872071, encodeId=ecb518e207166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 13:09:49 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905539, encodeId=267690553996, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Dec 06 23:25:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288312, encodeId=38d412883124b, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291737, encodeId=d66c1291e372c, content=<a href='/topic/show?id=62f68635461' target=_blank style='color:#2F92EE;'>#自身免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86354, encryptionId=62f68635461, topicName=自身免疫病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477217, encodeId=751514e72175e, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
    2020-11-26 lsndxfj
  9. [GetPortalCommentsPageByObjectIdResponse(id=1962373, encodeId=8fb919623e32e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 15 07:09:49 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896781, encodeId=1b511896e8155, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 20 20:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041785, encodeId=c0602041e851c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 29 07:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814549, encodeId=b7871814549a4, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Jun 22 10:09:49 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888245, encodeId=097f1888245e2, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Dec 27 20:09:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872071, encodeId=ecb518e207166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 13:09:49 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905539, encodeId=267690553996, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Dec 06 23:25:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288312, encodeId=38d412883124b, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291737, encodeId=d66c1291e372c, content=<a href='/topic/show?id=62f68635461' target=_blank style='color:#2F92EE;'>#自身免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86354, encryptionId=62f68635461, topicName=自身免疫病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477217, encodeId=751514e72175e, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1962373, encodeId=8fb919623e32e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 15 07:09:49 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896781, encodeId=1b511896e8155, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 20 20:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041785, encodeId=c0602041e851c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 29 07:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814549, encodeId=b7871814549a4, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Jun 22 10:09:49 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888245, encodeId=097f1888245e2, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Dec 27 20:09:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872071, encodeId=ecb518e207166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 13:09:49 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905539, encodeId=267690553996, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Dec 06 23:25:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288312, encodeId=38d412883124b, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291737, encodeId=d66c1291e372c, content=<a href='/topic/show?id=62f68635461' target=_blank style='color:#2F92EE;'>#自身免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86354, encryptionId=62f68635461, topicName=自身免疫病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477217, encodeId=751514e72175e, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Thu Nov 26 13:09:49 CST 2020, time=2020-11-26, status=1, ipAttribution=)]

相关资讯

Genome Med:武大孙承操等揭示LINC00301在非小细胞肺癌进展和肿瘤免疫中的重要作用

非小细胞肺癌(NSCLC)是全球癌症死亡的首要诱因,然而其发生进展的具体机制仍然需要进一步阐明。长链非编码RNA(lncRNA)是一类长度大于200个核苷酸单位(nt)的不具备完整蛋白编码能力的RNA

Cancer Cell:效果更强劲!廖学斌/魏来合作揭示HPK1可成为T细胞免疫疗法的靶点

改善T细胞衰竭和增强效应子功能是改善免疫疗法的有希望的策略。HPK1是癌症免疫疗法的有希望的候选靶标。但是尚未很好地确定HPK1在基于T细胞的免疫疗法中的功能意义以及HPK1抑制T细胞功能的分子机制。

Circulation:发现遗传性心律失常治疗靶点,首次建立人心脏微器官芯片疾病模型

由哈佛医学院波士顿儿童医院心脏科主任William T. Pu 教授和哈佛大学John A. Paulson工程与应用科学学院心脏微器官创始人Kevin Kit Parker教授研究组合作在Circulation杂志上发表文章Insights into the Pathogenesis of CatecholaminergicPolymorphic Ventricular Tachycardia

Nat Commun:前列腺癌中组蛋白甲基转移酶DOT1L能够协调AR和MYC的稳定性

组蛋白甲基转移酶DOT1L能够甲基化组蛋白H3上的赖氨酸79(K79),并与混合系白血病(MLL)融合白血病的发生有关;然而,DOT1L在前列腺癌(PCa)中的作用尚未确定。

Cancer Gene Therapy:LncRNA KCNQ1OT1能够促进膀胱癌进展

长非编码RNA(lncRNA)在各种癌症中具有生物学功能的特点。LncRNA KCNQ1 反向链/反义转录1 (KCNQ1OT1)被公认能够调控各种癌症,然而其在膀胱癌中的作用仍不清楚。

CDS2018:糖尿病肾脏病诊治的新靶点——肾小管上皮细胞

糖尿病所致的肾损害并不仅仅局限于肾小球,肾小管上皮细胞在糖尿病肾脏病(DKD)的早期和进展期均发挥了关键作用。2018年11月30日,在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)上,南方医科大学南方医院薛耀明教授从DKD防治的严峻形势入手,介绍了肾小管上皮细胞在DKD发病中的重要性以及肾小管上皮细胞作为DKD治疗新靶点的最新研究进展。